Which has better valuation and earnings, LFMD or SERA?

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 1.13 $14.35M $0.05 90.80 Sera Prognostics $80K 993.69 -$31.93M -$0.65 N/A

Is LFMD or SERA more profitable?

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 2.37% -150.88% -22.59% Sera Prognostics -56,385.97% -41.02% -30.95%

Does the media favor LFMD or SERA?

In the previous week, LifeMD and LifeMD both had 2 articles in the media. LifeMD's average media sentiment score of 0.93 beat Sera Prognostics' score of 0.63 indicating that LifeMD is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SERA or BDSX more profitable?

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Biodesix -33.26% -2,101.40% -35.65%

Does the media refer more to SERA or BDSX?

In the previous week, Biodesix had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for Sera Prognostics. Biodesix's average media sentiment score of 1.79 beat Sera Prognostics' score of 0.63 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has better earnings and valuation, SERA or XGN?

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sera Prognostics $80K 993.69 -$31.93M -$0.65 N/A Exagen $66.57M 1.71 -$19.95M -$0.89 N/A

Is SERA or XGN more profitable?

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets Sera Prognostics -56,385.97% -41.02% -30.95% Exagen -29.49% -94.37% -28.96%

Which has preferable earnings and valuation, PARK or SERA?

Park Dental Partners has higher revenue and earnings than Sera Prognostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Park Dental Partners $244.49M 0.37 -$360K N/A N/A Sera Prognostics $80K 993.69 -$31.93M -$0.65 N/A

Does the media prefer PARK or SERA?

In the previous week, Park Dental Partners had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for Sera Prognostics. Park Dental Partners' average media sentiment score of 1.12 beat Sera Prognostics' score of 0.63 indicating that Park Dental Partners is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Park Dental Partners 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SERA or PIII?

In the previous week, P3 Health Partners had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for P3 Health Partners and 2 mentions for Sera Prognostics. P3 Health Partners' average media sentiment score of 1.48 beat Sera Prognostics' score of 0.63 indicating that P3 Health Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sera Prognostics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive P3 Health Partners 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sera Prognostics (SERA) Competitors

$2.03 +0.21 (+11.54%)

Closing price 04:00 PM Eastern

Extended Trading

$2.02 -0.01 (-0.49%)

As of 04:10 PM Eastern

Compare

SERA vs. LFMD, BDSX, XGN, PARK, and PIII

Should you buy Sera Prognostics stock or one of its competitors? MarketBeat compares Sera Prognostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sera Prognostics include LifeMD (LFMD), Biodesix (BDSX), Exagen (XGN), Park Dental Partners (PARK), and P3 Health Partners (PIII). These companies are all part of the "healthcare" industry.

How does Sera Prognostics compare to LifeMD?

LifeMD (NASDAQ:LFMD) and Sera Prognostics (NASDAQ:SERA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

35.5% of LifeMD shares are held by institutional investors. Comparatively, 54.6% of Sera Prognostics shares are held by institutional investors. 17.2% of LifeMD shares are held by insiders. Comparatively, 11.3% of Sera Prognostics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, LifeMD and LifeMD both had 2 articles in the media. LifeMD's average media sentiment score of 0.93 beat Sera Prognostics' score of 0.63 indicating that LifeMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LifeMD has a net margin of 2.37% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	2.37%	-150.88%	-22.59%
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

LifeMD has higher revenue and earnings than Sera Prognostics. Sera Prognostics is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	1.13	$14.35M	$0.05	90.80
Sera Prognostics	$80K	993.69	-$31.93M	-$0.65	N/A

LifeMD has a beta of 1.99, suggesting that its stock price is 99% more volatile than the broader market. Comparatively, Sera Prognostics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

LifeMD currently has a consensus price target of $9.14, suggesting a potential upside of 101.38%. Sera Prognostics has a consensus price target of $5.50, suggesting a potential upside of 170.94%. Given Sera Prognostics' higher possible upside, analysts plainly believe Sera Prognostics is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

LifeMD beats Sera Prognostics on 11 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Biodesix?

Sera Prognostics (NASDAQ:SERA) and Biodesix (NASDAQ:BDSX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Biodesix has a net margin of -33.26% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Biodesix	-33.26%	-2,101.40%	-35.65%

Sera Prognostics currently has a consensus target price of $5.50, indicating a potential upside of 170.94%. Biodesix has a consensus target price of $28.33, indicating a potential upside of 15.65%. Given Sera Prognostics' higher possible upside, analysts plainly believe Sera Prognostics is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

54.6% of Sera Prognostics shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 11.3% of Sera Prognostics shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sera Prognostics has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.52, indicating that its share price is 48% less volatile than the broader market.

Sera Prognostics has higher earnings, but lower revenue than Biodesix. Biodesix is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	993.69	-$31.93M	-$0.65	N/A
Biodesix	$88.50M	2.87	-$35.26M	-$4.06	N/A

In the previous week, Biodesix had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Biodesix and 2 mentions for Sera Prognostics. Biodesix's average media sentiment score of 1.79 beat Sera Prognostics' score of 0.63 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Sera Prognostics beats Biodesix on 9 of the 16 factors compared between the two stocks.

How does Sera Prognostics compare to Exagen?

Sera Prognostics (NASDAQ:SERA) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.

Exagen has higher revenue and earnings than Sera Prognostics. Exagen is trading at a lower price-to-earnings ratio than Sera Prognostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	993.69	-$31.93M	-$0.65	N/A
Exagen	$66.57M	1.71	-$19.95M	-$0.89	N/A

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 170.94%. Exagen has a consensus price target of $9.11, indicating a potential upside of 93.44%. Given Sera Prognostics' higher possible upside, research analysts plainly believe Sera Prognostics is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
Exagen	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Sera Prognostics and Sera Prognostics both had 2 articles in the media. Exagen's average media sentiment score of 1.93 beat Sera Prognostics' score of 0.63 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
Sera Prognostics	Positive
Exagen	Very Positive

Sera Prognostics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Exagen has a beta of 2.02, indicating that its stock price is 102% more volatile than the broader market.

Exagen has a net margin of -29.49% compared to Sera Prognostics' net margin of -56,385.97%. Sera Prognostics' return on equity of -41.02% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
Exagen	-29.49%	-94.37%	-28.96%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 10.4% of Exagen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Exagen beats Sera Prognostics on 9 of the 15 factors compared between the two stocks.

How does Sera Prognostics compare to Park Dental Partners?

Park Dental Partners (NASDAQ:PARK) and Sera Prognostics (NASDAQ:SERA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, profitability, earnings, analyst recommendations and institutional ownership.

Park Dental Partners has a net margin of 0.00% compared to Sera Prognostics' net margin of -56,385.97%. Park Dental Partners' return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Park Dental Partners	N/A	N/A	N/A
Sera Prognostics	-56,385.97%	-41.02%	-30.95%

Park Dental Partners currently has a consensus target price of $21.75, indicating a potential upside of 7.35%. Sera Prognostics has a consensus target price of $5.50, indicating a potential upside of 170.94%. Given Sera Prognostics' higher probable upside, analysts plainly believe Sera Prognostics is more favorable than Park Dental Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Park Dental Partners	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	2 Strong Buy rating(s)	2.75
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

54.6% of Sera Prognostics shares are owned by institutional investors. 10.6% of Park Dental Partners shares are owned by company insiders. Comparatively, 11.3% of Sera Prognostics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Park Dental Partners has higher revenue and earnings than Sera Prognostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Park Dental Partners	$244.49M	0.37	-$360K	N/A	N/A
Sera Prognostics	$80K	993.69	-$31.93M	-$0.65	N/A

In the previous week, Park Dental Partners had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for Park Dental Partners and 2 mentions for Sera Prognostics. Park Dental Partners' average media sentiment score of 1.12 beat Sera Prognostics' score of 0.63 indicating that Park Dental Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Park Dental Partners	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Park Dental Partners beats Sera Prognostics on 9 of the 14 factors compared between the two stocks.

How does Sera Prognostics compare to P3 Health Partners?

Sera Prognostics (NASDAQ:SERA) and P3 Health Partners (NASDAQ:PIII) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Sera Prognostics has higher earnings, but lower revenue than P3 Health Partners. Sera Prognostics is trading at a lower price-to-earnings ratio than P3 Health Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sera Prognostics	$80K	993.69	-$31.93M	-$0.65	N/A
P3 Health Partners	$1.46B	0.05	-$147.95M	-$38.60	N/A

Sera Prognostics currently has a consensus price target of $5.50, indicating a potential upside of 170.94%. P3 Health Partners has a consensus price target of $14.00, indicating a potential upside of 26.47%. Given Sera Prognostics' stronger consensus rating and higher possible upside, analysts clearly believe Sera Prognostics is more favorable than P3 Health Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sera Prognostics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
P3 Health Partners	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sera Prognostics has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, P3 Health Partners has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

P3 Health Partners has a net margin of -8.57% compared to Sera Prognostics' net margin of -56,385.97%. P3 Health Partners' return on equity of 0.00% beat Sera Prognostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sera Prognostics	-56,385.97%	-41.02%	-30.95%
P3 Health Partners	-8.57%	N/A	-19.99%

54.6% of Sera Prognostics shares are held by institutional investors. Comparatively, 7.8% of P3 Health Partners shares are held by institutional investors. 11.3% of Sera Prognostics shares are held by company insiders. Comparatively, 10.9% of P3 Health Partners shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, P3 Health Partners had 1 more articles in the media than Sera Prognostics. MarketBeat recorded 3 mentions for P3 Health Partners and 2 mentions for Sera Prognostics. P3 Health Partners' average media sentiment score of 1.48 beat Sera Prognostics' score of 0.63 indicating that P3 Health Partners is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sera Prognostics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
P3 Health Partners	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Sera Prognostics and P3 Health Partners tied by winning 8 of the 16 factors compared between the two stocks.

Get Sera Prognostics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SERA vs. The Competition

Export

Metric	Sera Prognostics	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$71.27M	$9.33B	$6.81B	$12.59B
Dividend Yield	N/A	1.66%	2.67%	6.15%
P/E Ratio	-3.12	26.82	27.67	25.27
Price / Sales	993.69	18.73	533.25	101.15
Price / Cash	N/A	111.99	47.99	59.26
Price / Book	1.05	6.12	10.96	6.62
Net Income	-$31.93M	$179.69M	$3.57B	$336.83M
7 Day Performance	12.78%	5.26%	2.58%	2.52%
1 Month Performance	-7.31%	8.09%	1.67%	0.44%
1 Year Performance	-21.62%	14.73%	35.96%	29.40%

Sera Prognostics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SERA Sera Prognostics	3.3296 of 5 stars	$2.03 +11.5%	$5.50 +170.9%	-34.3%	$71.27M	$80K	N/A	120	News Coverage
LFMD LifeMD	2.7591 of 5 stars	$4.55 +5.6%	$9.14 +100.9%	-69.8%	$208.45M	$193.33M	91.02	230
BDSX Biodesix	3.6005 of 5 stars	$19.16 +10.4%	$26.50 +38.3%	+299.5%	$179.68M	$96.10M	N/A	220	Positive News
XGN Exagen	4.3296 of 5 stars	$4.36 -1.4%	$9.25 +112.2%	-33.4%	$106.79M	$68.38M	N/A	220	Gap Down
PARK Park Dental Partners	3.177 of 5 stars	$17.55 -3.3%	$21.75 +23.9%	N/A	$81.95M	$244.49M	N/A	1,208

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SERA) was last updated on 7/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sera Prognostics (SERA) Competitors

SERA vs. LFMD, BDSX, XGN, PARK, and PIII

How does Sera Prognostics compare to LifeMD?

Summary

How does Sera Prognostics compare to Biodesix?

Summary

How does Sera Prognostics compare to Exagen?

Summary

How does Sera Prognostics compare to Park Dental Partners?

Summary

How does Sera Prognostics compare to P3 Health Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sera Prognostics (SERA) Competitors

SERA vs. LFMD, BDSX, XGN, PARK, and PIII

How does Sera Prognostics compare to LifeMD?

Do insiders & institutionals hold more shares of LFMD or SERA?

Does the media favor LFMD or SERA?

Is LFMD or SERA more profitable?

Which has better valuation and earnings, LFMD or SERA?

Which has more volatility & risk, LFMD or SERA?

Do analysts recommend LFMD or SERA?

Summary

How does Sera Prognostics compare to Biodesix?

Is SERA or BDSX more profitable?

Do analysts prefer SERA or BDSX?

Do insiders and institutionals have more ownership in SERA or BDSX?

Which has more volatility and risk, SERA or BDSX?

Which has stronger valuation and earnings, SERA or BDSX?

Does the media refer more to SERA or BDSX?

Summary

How does Sera Prognostics compare to Exagen?

Which has better earnings and valuation, SERA or XGN?

Do analysts rate SERA or XGN?

Does the media refer more to SERA or XGN?

Which has more volatility and risk, SERA or XGN?

Is SERA or XGN more profitable?

Do institutionals & insiders have more ownership in SERA or XGN?

Summary

How does Sera Prognostics compare to Park Dental Partners?

Is PARK or SERA more profitable?

Do analysts prefer PARK or SERA?

Do institutionals and insiders have more ownership in PARK or SERA?

Which has preferable earnings and valuation, PARK or SERA?

Does the media prefer PARK or SERA?

Summary

How does Sera Prognostics compare to P3 Health Partners?

Which has higher earnings and valuation, SERA or PIII?

Do analysts prefer SERA or PIII?

Which has more risk & volatility, SERA or PIII?

Is SERA or PIII more profitable?

Do institutionals & insiders believe in SERA or PIII?

Does the media refer more to SERA or PIII?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SERA vs. The Competition

Sera Prognostics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools